Talon Private Wealth LLC Purchases 1,630 Shares of United Therapeutics Corporation $UTHR

Talon Private Wealth LLC increased its position in United Therapeutics Corporation (NASDAQ:UTHR) by 31.8% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 6,753 shares of the biotechnology company’s stock after buying an additional 1,630 shares during the quarter. Talon Private Wealth LLC’s holdings in United Therapeutics were worth $3,659,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in the business. California State Teachers Retirement System grew its holdings in United Therapeutics by 55,526.2% during the 2nd quarter. California State Teachers Retirement System now owns 33,288,952 shares of the biotechnology company’s stock worth $18,036,953,000 after acquiring an additional 33,229,108 shares during the last quarter. BlackRock Inc. bought a new position in shares of United Therapeutics during the second quarter valued at $2,868,735,000. Wellington Management Group LLP lifted its holdings in shares of United Therapeutics by 74.5% during the fourth quarter. Wellington Management Group LLP now owns 2,441,492 shares of the biotechnology company’s stock worth $1,189,617,000 after purchasing an additional 1,042,711 shares during the period. Jupiter Topco LLC acquired a new position in shares of United Therapeutics during the second quarter worth $450,140,000. Finally, Norges Bank bought a new stake in shares of United Therapeutics in the fourth quarter worth $293,418,000. Institutional investors own 94.08% of the company’s stock.

Insider Activity at United Therapeutics

In other news, CEO Martine A. Rothblatt sold 9,500 shares of United Therapeutics stock in a transaction on Monday, June 15th. The shares were sold at an average price of $549.15, for a total value of $5,216,925.00. Following the completion of the sale, the chief executive officer owned 40,513 shares in the company, valued at $22,247,713.95. The trade was a 19.00% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO James Edgemond sold 10,000 shares of the stock in a transaction on Thursday, June 18th. The stock was sold at an average price of $540.15, for a total transaction of $5,401,500.00. Following the transaction, the chief financial officer directly owned 18,876 shares in the company, valued at approximately $10,195,871.40. This represents a 34.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last three months, insiders sold 384,075 shares of company stock worth $202,367,758. Insiders own 8.60% of the company’s stock.

Analyst Ratings Changes

Several research analysts recently issued reports on UTHR shares. TD Cowen reaffirmed a “buy” rating on shares of United Therapeutics in a research report on Thursday, May 21st. JPMorgan Chase & Co. upped their price target on United Therapeutics from $685.00 to $687.00 and gave the company an “overweight” rating in a research report on Thursday, July 23rd. Royal Bank Of Canada decreased their price target on United Therapeutics from $704.00 to $677.00 and set an “outperform” rating for the company in a research note on Thursday, August 6th. Bank of America lowered their price objective on United Therapeutics from $620.00 to $613.00 and set a “neutral” rating for the company in a research report on Friday, July 10th. Finally, Morgan Stanley set a $515.00 target price on United Therapeutics in a report on Thursday, August 6th. Eleven equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus target price of $646.00.

United Therapeutics Stock Performance

Shares of UTHR stock traded down $6.75 during mid-day trading on Friday, hitting $497.11. The company’s stock had a trading volume of 359,358 shares, compared to its average volume of 494,315. The company’s fifty day simple moving average is $522.08 and its 200-day simple moving average is $540.60. United Therapeutics Corporation has a 52 week low of $396.12 and a 52 week high of $609.35. The company has a market cap of $21.32 billion, a PE ratio of 17.79, a P/E/G ratio of 2.53 and a beta of 0.56.

United Therapeutics (NASDAQ:UTHR) last announced its earnings results on Wednesday, August 5th. The biotechnology company reported $7.27 EPS for the quarter, beating the consensus estimate of $6.86 by $0.41. United Therapeutics had a return on equity of 20.18% and a net margin of 41.56%.The company had revenue of $783.30 million for the quarter, compared to analyst estimates of $804.65 million. During the same quarter in the prior year, the company earned $6.41 EPS. The firm’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities analysts anticipate that United Therapeutics Corporation will post 26.33 earnings per share for the current year.

About United Therapeutics

United Therapeutics Corporation is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening conditions, with a primary emphasis on pulmonary arterial hypertension (PAH). The company’s products are designed to improve pulmonary blood flow and reduce the effects of this progressive disease.

United Therapeutics’ PAH portfolio includes Remodulin (treprostinil) injection, Orenitram (treprostinil) extended-release tablets, and Tyvaso (treprostinil), which is available as an inhalation solution and as the Tyvaso DPI dry-powder inhaler.